Cargando…

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure

BACKGROUND: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. METHODS: We searched PubMed, Web of Scie...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Dong-Hui, Sun, Hao, Shi, Jing-Pu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804439/
https://www.ncbi.nlm.nih.gov/pubmed/26904992
http://dx.doi.org/10.4103/0366-6999.177000
_version_ 1782423021175177216
author Huang, Dong-Hui
Sun, Hao
Shi, Jing-Pu
author_facet Huang, Dong-Hui
Sun, Hao
Shi, Jing-Pu
author_sort Huang, Dong-Hui
collection PubMed
description BACKGROUND: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. METHODS: We searched PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database from inception to April 2015. Studies that investigated the diagnostic role of sST2 for HF were reviewed. The numbers of true-positive, false-positive, false-negative, and true-negative results were extracted to calculate pooled diagnostic odds ratio (DOR) with 95% confidence interval (CI) and the summary receiver operating characteristic curve and area under the curve (AUC). The Spearman correlation coefficient was used to check the threshold effect. The Cochran Q statistic (P < 0.05) and the inconsistency index (I(2) > 50%) were used to assess the nonthreshold effect. Meta-regression was conducted to explore the source of heterogeneity; subgroup analysis showed the results in different subgroups. Finally, the Deeks’ test was performed to assess the publication bias. RESULTS: Nine articles including 10 studies were included in the meta-analysis. The pooled sensitivity was 0.84 (95% CI: 0.81–0.86), and pooled specificity was 0.74 (95% CI: 0.72–0.76). The summary DOR was 8.49 (95% CI: 4.54–15.86), and AUC was 0.81 (standard error: 0.03). The Spearman correlation coefficient identified the nonsignificant threshold effect (coefficient = 0.49, P = 0.148), but the nonthreshold effect heterogeneity was significant (Cochran Q = 58.52, P < 0.0001; I(2) = 84.6%). Meta-regression found that characteristics of controls might be the suggestive source of nonthreshold effect heterogeneity (P = 0.095). Subgroup analysis found that DOR was 5.65 and 7.86, respectively for the controls of hospital patients and healthy populations. Deeks’ test demonstrated that there was no publication bias (P = 0.616). CONCLUSION: The meta-analysis illustrated that sST2 might play a role in diagnosing HF.
format Online
Article
Text
id pubmed-4804439
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48044392016-04-04 Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure Huang, Dong-Hui Sun, Hao Shi, Jing-Pu Chin Med J (Engl) Meta Analysis BACKGROUND: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. METHODS: We searched PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database from inception to April 2015. Studies that investigated the diagnostic role of sST2 for HF were reviewed. The numbers of true-positive, false-positive, false-negative, and true-negative results were extracted to calculate pooled diagnostic odds ratio (DOR) with 95% confidence interval (CI) and the summary receiver operating characteristic curve and area under the curve (AUC). The Spearman correlation coefficient was used to check the threshold effect. The Cochran Q statistic (P < 0.05) and the inconsistency index (I(2) > 50%) were used to assess the nonthreshold effect. Meta-regression was conducted to explore the source of heterogeneity; subgroup analysis showed the results in different subgroups. Finally, the Deeks’ test was performed to assess the publication bias. RESULTS: Nine articles including 10 studies were included in the meta-analysis. The pooled sensitivity was 0.84 (95% CI: 0.81–0.86), and pooled specificity was 0.74 (95% CI: 0.72–0.76). The summary DOR was 8.49 (95% CI: 4.54–15.86), and AUC was 0.81 (standard error: 0.03). The Spearman correlation coefficient identified the nonsignificant threshold effect (coefficient = 0.49, P = 0.148), but the nonthreshold effect heterogeneity was significant (Cochran Q = 58.52, P < 0.0001; I(2) = 84.6%). Meta-regression found that characteristics of controls might be the suggestive source of nonthreshold effect heterogeneity (P = 0.095). Subgroup analysis found that DOR was 5.65 and 7.86, respectively for the controls of hospital patients and healthy populations. Deeks’ test demonstrated that there was no publication bias (P = 0.616). CONCLUSION: The meta-analysis illustrated that sST2 might play a role in diagnosing HF. Medknow Publications & Media Pvt Ltd 2016-03-05 /pmc/articles/PMC4804439/ /pubmed/26904992 http://dx.doi.org/10.4103/0366-6999.177000 Text en Copyright: © 2016 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Meta Analysis
Huang, Dong-Hui
Sun, Hao
Shi, Jing-Pu
Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title_full Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title_fullStr Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title_full_unstemmed Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title_short Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
title_sort diagnostic value of soluble suppression of tumorigenicity-2 for heart failure
topic Meta Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804439/
https://www.ncbi.nlm.nih.gov/pubmed/26904992
http://dx.doi.org/10.4103/0366-6999.177000
work_keys_str_mv AT huangdonghui diagnosticvalueofsolublesuppressionoftumorigenicity2forheartfailure
AT sunhao diagnosticvalueofsolublesuppressionoftumorigenicity2forheartfailure
AT shijingpu diagnosticvalueofsolublesuppressionoftumorigenicity2forheartfailure